Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

NCT ID: NCT00538915

Last Updated: 2021-07-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-09-30
• Study Completion Date: 2009-07-31

Brief Summary

The purpose of this study is to determine if NABI-IGIV (10%) [Immune Globulin Intravenous (Human), 10%] is safe and effective in preventing serious bacterial infections (SBIs) in the treatment of patients with primary immune deficiency disorders (PIDD) when compared to historical control data.

Conditions

Primary Immune Deficiency Disorders (PIDD)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Nabi-IGIV Infused Every 3- or 4-Weeks

Group Type: EXPERIMENTAL

Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

Intervention Type: BIOLOGICAL

Nabi-IGIV 10% \[Immune Globulin Intravenous (Human), 10%\] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.

Interventions

Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

Nabi-IGIV 10% \[Immune Globulin Intravenous (Human), 10%\] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Male or female, age ≥ 6 and ≤ 75, with a documented and confirmed pre-existing diagnosis of chronic primary immune deficiency (PIDD) with a low total immunoglobulin G (IgG) level and deficient antibody production before chronic therapy (i.e., X-linked agammaglobulinemia, common variable immunodeficiency (CVID), Hyper IgM Syndrome with immunoglobulin G (IgG) deficiency, etc).
• Currently on immune globulin intravenous (IGIV) replacement therapy at a fixed interval and dosage with a total monthly dose of immune globulin intravenous (IGIV) between 300 and 800 mg/kg that has been stable for at least 3 months prior to screening.
• Documented (within 3 months) plasma immunoglobulin G (IgG) trough level of >500 mg/dL on current immunoglobulin G (IgG) therapy [immunoglobulin G (IgG) levels may be obtained at screening if previous results not available].
• Medical records documenting infections and treatment within the previous 2 years need to be available for review.
• Subject or legal guardian(s) must have given written informed consent/assent.
• If a menstruating female, have a negative serum or urine pregnancy test within 7 days prior to the first dose of Nabi-IGIV [immune globulin intravenous (Human) 10%] and agree to use an acceptable method of contraception or be at least one year post-menopausal or surgically sterile.

Exclusion Criteria

• Received any blood product [other than immune globulin intravenous (IGIV)] within the last 3 months prior to screening or received any investigational agent [other than immune globulin intravenous (IGIV)] within the last four weeks prior to receiving Nabi-IGIV [immune globulin intravenous (Human) 10%].
• Known history of medically significant adverse reactions to other immunoglobulin G (IgG) or blood products.
• Known selective immunoglobulin A (IgA) deficiency, history of allergic reaction to products containing immunoglobulin A (IgA) or has a history of antibodies to immunoglobulin A (IgA).
• Known significant proteinuria and/or has a history of acute renal failure/or severe renal impairment [blood urea nitrogen (BUN) or creatinine more than 1.5 times the upper limit of normal].
• Known history or current diagnosis of deep venous thrombosis.
• Known medical condition that is known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, human immunodeficiency virus (HIV) infection, acquired immunodeficiency syndrome (AIDS), or chronic or recurrent neutropenia (absolute neutrophil count less than 500 mm3).
• Current daily use of corticosteroids (> 10 mg of prednisone equivalent /day for > 30 days), immunosuppressants or immunomodulators. (Intermittent corticosteroid use during the study is allowable, if medically necessary.)
• Known non-controllable arterial hypertension (systolic blood pressure (BP) > 160 mmHg and /or diastolic BP >100 mmHg.)
• Known anemia at screening (hemoglobin <10 g/dL).
• Subject is pregnant or lactating.
• Known history of illicit drug use within 3 months prior to the administration of the investigational product and for the study duration.
• Have any condition judged by the study physician to preclude participation in the study, including any psychological disorder, which might hinder compliance.
• Known active viral or bacterial infection or symptoms/signs consistent with such an infection within the two weeks prior to the initial dose of investigational product infusion. Subjects may be on antibiotics as long as signs/symptoms of infection have been absent for two weeks prior to the initial infusion of investigational product (IP).
• Expectation of non-compliance with the protocol procedures and visit schedule.

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ADMA Biologics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Shailesh Chavan, M.D.

Role: STUDY_DIRECTOR

Biotest Pharmaceuticals Corporation

Locations

University of Alabama

Birmingham, Alabama, United States

Precision Trials LLC

Phoenix, Arizona, United States

Children's Hospital of Los Angeles

Los Angeles, California, United States

1st Allergy and Clinical Resaerch center

Centennial, Colorado, United States

Allergy Associates of the Palm Beaches

North Palm Beach, Florida, United States

Marietta Pulmonary Medicine

Marietta, Georgia, United States

Rush University Medical center

Chicago, Illinois, United States

South Bend Clinic LLP

South Bend, Indiana, United States

Kentuky Lung Clinic, PSC

Hazard, Kentucky, United States

Institute For Allergy & Asthma

Wheaton, Maryland, United States

Cardinal Glennon Children's MC

St Louis, Missouri, United States

Women's and Children's Hospital of Buffalo

Buffalo, New York, United States

University Hospital Case medical center

Cleveland, Ohio, United States

Allergy/Immunology Research Center of north Texas

Dallas, Texas, United States

AARA Research

Dallas, Texas, United States

Allergy, Asthma & Immunology Clinic, PA

Irving, Texas, United States

Bellingham Asthma, Allergy Clinic

Bellingham, Washington, United States

Countries

United States

Other Identifiers

Nabi-7101

Identifier Type: -

Identifier Source: org_study_id